The END RHD CRE: Developing an endgame for rheumatic heart disease in Australia

END RHD CRE：为澳大利亚风湿性心脏病制定最终方案

• 批准号: nhmrc : GNT1080401
• 负责人: A/Pr Anna Ralph
• 金额: $ 249.68万
• 依托单位国家: 澳大利亚
• 项目类别: Centres of Research Excellence
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/end-rhd-cre-disease-australia/1345350
• 关键词: END; RHD; CRE; Developing; endgame

Rheumatic heart disease (RHD) is caused by an abnormal immune reaction to some bacterial infections. Although RHD is rare in developed countries, Indigenous Australians still live with the burden of RHD. The END RHD CRE will explore risk factors for RHD, prevention with antibiotics, management of RHD and the potential for vaccine development. Individuals and communities experiencing RHD are integral partners to this work. The CRE will establish a strategy for ending RHD in Australia.

风湿性心脏病（RHD）是由对某些细菌感染的异常免疫反应引起的。虽然RHD在发达国家很少见，但澳大利亚土著居民仍然生活在RHD的负担之下。END RHD CRE将探讨RHD的危险因素、抗生素预防、RHD管理和疫苗开发的潜力。经历RHD的个人和社区是这项工作不可或缺的合作伙伴。CRE将制定在澳大利亚结束RHD的战略。